The Daily Overview on MSN
Nvidia teams with biotech giants to supercharge AI drug discovery
Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...
Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...
Grab-and-go missions to asteroids have provided some of the most scientifically valuable samples since the Apollo ...
Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly. On December 17, 2025, JPMorgan ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...
The original version of this story appeared in Quanta Magazine. Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback